Literature DB >> 17979715

The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory.

Christian Bronner1, Thierry Chataigneau, Valérie B Schini-Kerth, Yves Landry.   

Abstract

Discrete chemical modifications of the chromatin (DNA and primarily histones) can regulate gene expression or repression and can be transmitted to the descent (cells or organisms) thanks to an epigenetic memory. These modifications involve histone post-translational modifications, DNA methylation at CpG islands and small nuclear RNAs processes. They play fundamental roles in cell proliferation and differentiation. These two processes are crucial in particular during embryonic development, X chromosome inactivation in females, genomic imprinting, gene bookmarking, cell reprogramming, position effect and silencing of retroviral elements. While, only one major DNA modification is known, more than 150 post-translation modifications of histones have been reported, including methylations, acetylations, ubiquitinations, SUMOylations and phosphorylations. How these modifications are inherited from mother cells to daughter cells or from an organism to its descent remains a major scientific challenge. We propose here a macro-molecular complex, called ECREM for "Epigenetic Code REplication Machinery", as being involved in the inheritance of the epigenetic code. The composition of ECREM may vary in a spatio-temporal manner according to the chromatin state, the cell phenotype and the development stage. We describe the members of ECREM, responsible for the epigenetic code inheritance, i.e., enzymes involved in DNA methylation and histone post-translational modifications. Some of them, such as DNA methyltransferases (DNMTs), histone acetyltransferases (HATs) and histone deacetylases (HDACS including sirtuins), have been found to be deregulated in several types of pathologies and are already targeted by inhibitors. ECREM, thus, appears to be an interesting complex to be investigated in order to find new drugs for cancer, metabolic, neuro-degenerative and inflammatory diseases therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979715     DOI: 10.2174/092986707782023244

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  The evolution of epitype.

Authors:  Richard B Meagher
Journal:  Plant Cell       Date:  2010-06-15       Impact factor: 11.277

Review 2.  Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Authors:  Mahmoud Alhosin; Tanveer Sharif; Marc Mousli; Nelly Etienne-Selloum; Guy Fuhrmann; Valérie B Schini-Kerth; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2011-04-15

Review 3.  Epigenetic principles and mechanisms underlying nervous system functions in health and disease.

Authors:  Mark F Mehler
Journal:  Prog Neurobiol       Date:  2008-10-17       Impact factor: 11.685

4.  Analysis of the Hox epigenetic code.

Authors:  Zoheir Ezziane
Journal:  World J Clin Oncol       Date:  2012-04-10

5.  UHRF1 Links the Histone code and DNA Methylation to ensure Faithful Epigenetic Memory Inheritance.

Authors:  Christian Bronner; Guy Fuhrmann; Frédéric L Chédin; Marcella Macaluso; Sirano Dhe-Paganon
Journal:  Genet Epigenet       Date:  2010-01-14

6.  Epigenetic perturbations in the pathogenesis of mustard toxicity; hypothesis and preliminary results.

Authors:  Ahmet Korkmaz; Hakan Yaren; Z Ilker Kunak; Bulent Uysal; Bulent Kurt; Turgut Topal; Levent Kenar; Ergun Ucar; Sukru Oter
Journal:  Interdiscip Toxicol       Date:  2008-12

7.  Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically.

Authors:  Joan Oliva; Jennifer Dedes; Jun Li; Samuel-W French; Fawzia Bardag-Gorce
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

8.  Inhibiting UHRF1 expression enhances radiosensitivity in human esophageal squamous cell carcinoma.

Authors:  Congrong Yang; Yadi Wang; Fuli Zhang; Guogui Sun; Chenglin Li; Shaowu Jing; Qing Liu; Yunjie Cheng
Journal:  Mol Biol Rep       Date:  2013-08-13       Impact factor: 2.316

9.  Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy.

Authors:  Hani Choudhry; Mazin A Zamzami; Ziad Omran; Wei Wu; Marc Mousli; Christian Bronner; Mahmoud Alhosin
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

Review 10.  Epigenetics in heart failure phenotypes.

Authors:  Alexander Berezin
Journal:  BBA Clin       Date:  2016-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.